Loading...
XNAS
VCYT
Market cap3.43bUSD
Oct 08, Last price  
43.60USD
1D
1.02%
1Q
-23.47%
Jan 2017
463.31%
IPO
251.90%
Name

Veracyte Inc

Chart & performance

D1W1MN
XNAS:VCYT chart
P/E
52.43
P/S
6.73
EPS
0.83
Div yield, %
—
Shrs. gr., 5y
8.64%
Rev. gr., 5y
34.50%
Revenues
517m
+16.01%
2,645,00011,628,00021,884,00038,190,00049,503,00065,085,00071,953,00092,008,000120,368,000117,483,000219,514,000296,536,000361,051,000445,764,000517,145,000
Net income
66m
+174.89%
-14,445,000-18,649,000-25,580,000-29,373,000-33,704,000-31,358,000-31,003,000-22,999,000-12,599,000-34,909,000-75,563,000-36,560,000-74,404,00024,138,00066,353,000
CFO
136m
+81.51%
-13,524,000-7,167,000-19,159,000-27,632,000-26,965,000-27,982,000-23,915,000-13,521,000-3,232,000-9,711,000-31,621,0007,535,00044,222,00075,096,000136,307,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Key people

Rebecca Chambers
Chief Financial Officer · since 2021
Annie Mcguire
Chief Human Resources Officer, General Counsel · since 2023
Phillip Febbo
Chief Scientific Officer, Chief Medical Officer · since 2023
John Leite
Global Chief Commercial Officer · since 2024
Marc Stapley
Chief Executive Officer, Director · since 2021
Eliav Barr
Independent Director · since 2022
Muna Bhanji
Independent Director · since 2021
Karin Eastham
Independent Director · since 2012
Robert Epstein
Independent Chairman of the Board · since 2022
Jens Holstein
Independent Director · since 2020
Evan Jones
Independent Director · since 2008
Tom Miller
Independent Director · since 2024
Brent Shafer
Independent Director · since 2024
URL
https://www.veracyte.com/
IPO date
Oct 30, 2013
Employees
787
Domiciled in
US
Incorporated in
US
Legal address
c/o NATIONAL REGISTERED AGENTS, INC., 160 GREENTREE DR STE 101
DOVER, DE 19904
US
Headquarters
6000 Shoreline Court, Suite 300
South San Francisco, CA 94080
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT